[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100641336":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":36,"centralContacts":41,"locations":46,"responsibleParty":80,"collaborators":11,"id":82,"slug":83,"hasResults":84,"nctId":85,"briefTitle":86,"officialTitle":87,"acronym":11,"eligibilityCriteria":88,"healthyVolunteers":84,"sex":89,"minAge":90,"maxAge":11,"enrollmentInfo":91,"targetDuration":11,"studyType":94,"phases":95,"briefSummary":97,"conditions":98,"keywords":103,"overallStatus":49,"whyStopped":11,"lastUpdateSubmitDate":110,"lastUpdatePostDateStruct":111,"startDateStruct":114,"completionDateStruct":116,"leadSponsor":118,"locationsCount":119},{"fullName":5,"class":6},"Alpha-9 Oncology USA Inc.","INDUSTRY",[8,17],{"label":9,"type":10,"description":11,"interventionNames":12},"Phase 1 Dose Escalation","EXPERIMENTAL",null,[13,14,15,16],"Diagnostic Test: [68Ga]Ga-A9-6217","Diagnostic Test: Low dose [177Lu]Lu-A9-0631","Drug: [177Lu]Lu-A9-0631","Drug: [225Ac]Ac-A9-0642",{"label":18,"type":10,"description":11,"interventionNames":19},"Phase 1B Dose Expansion",[13,14,15,16],[21,26,29,33],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":11},"DIAGNOSTIC_TEST","[68Ga]Ga-A9-6217","Administered IV",[9,18],{"type":22,"name":27,"description":24,"armGroupLabels":28,"otherNames":11},"Low dose [177Lu]Lu-A9-0631",[9,18],{"type":30,"name":31,"description":24,"armGroupLabels":32,"otherNames":11},"DRUG","[177Lu]Lu-A9-0631",[9,18],{"type":30,"name":34,"description":24,"armGroupLabels":35,"otherNames":11},"[225Ac]Ac-A9-0642",[9,18],[37],{"name":38,"affiliation":39,"role":40},"Stephen Hull, MD","Alpha 9 Oncology","STUDY_DIRECTOR",[42],{"name":38,"role":43,"phone":44,"phoneExt":11,"email":45},"CONTACT","+1-778-715-3303","shull@a9oncology.com",[47,62],{"facility":48,"status":49,"city":50,"state":51,"zip":52,"country":53,"countryCode":54,"cosmosGeoPoint":11,"geoPoint":11,"contacts":55},"Melbourne Theranostic Innovation Center","RECRUITING","Melbourne N.","Victoria","3051","Australia","AU",[56,60],{"name":57,"role":43,"phone":58,"phoneExt":11,"email":59},"Prof. Rod Hicks","+61 03 9454 5800","rod.hicks@premit.net.au",{"name":57,"role":61,"phone":11,"phoneExt":11,"email":11},"PRINCIPAL_INVESTIGATOR",{"facility":63,"status":64,"city":65,"state":66,"zip":67,"country":53,"countryCode":54,"cosmosGeoPoint":68,"geoPoint":73,"contacts":74},"GenesisCare Murdoch","NOT_YET_RECRUITING","Murdoch","Western Australia","6150",{"type":69,"coordinates":70},"Point",[71,72],115.83757,-32.06987,{"lat":72,"lon":71},[75,79],{"name":76,"role":43,"phone":77,"phoneExt":11,"email":78},"Prof. Joe Cardaci","+610893661500","joe.cardaci@genesiscare.com",{"name":76,"role":61,"phone":11,"phoneExt":11,"email":11},{"type":81,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100641336","phase-1-a-study-of-177lulu-a9-0631-and-225acac-a9-0642-with-68gaga-a9-6217-or-177lulu-a9-0631-imaging-in-grpr-solid-tumors-100641336",false,"NCT07661641","A Study of [177Lu]Lu-A9-0631 and [225Ac]Ac-A9-0642 With [68Ga]Ga-A9-6217 or [177Lu]Lu-A9-0631 Imaging in GRPR+ Solid Tumors","A Phase 1-1b Study to Evaluate the Safety, Efficacy, and Dosimetry of [177Lu]Lu-A9-0631, [225Ac]Ac-A9-0642, and [68Ga]Ga-A9-6217 in Participants With GRPR+ Tumors","Inclusion Criteria:\n\n* Participant has provided written informed consent prior to any study-specific procedure.\n* Age ≥ 18 years old.\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1.\n* Have measurable target lesion per RECIST v1.1.\n* Progression from, intolerant to, or ineligible for (due to unavailability or contraindication) local standard of care therapies and have one of the following locally advanced or metastatic tumor types: prostate cancer; HR+\u002FHER2- breast cancer; colorectal cancer; and GRPR-positive solid tumors.\n* Have GRPR-expressing disease as confirmed by PET \u002F CT or SPECT imaging.\n* Adequate organ function within 14 days of first administration of investigational therapeutic product.\n* At least 4 weeks from prior major surgery.\n\nExclusion Criteria:\n\n* Received anticancer treatment including but not limited to chemotherapy, antibody therapy, immunotherapy, gene therapy, vaccine therapy, angiogenesis inhibitors, or experimental drugs ≤ 14 days prior (≤ 28 days prior in case of checkpoint inhibitor therapy and other antibody therapies) or 5 half-lives, (t1\u002F2) whichever is shorter, to the administration of therapeutic investigational product.\n* History of uncontrolled allergic reactions and\u002For known or expected hypersensitivity to a peptide-based imaging or therapeutic agent or any excipient present in either of the therapeutic investigational products.\n* Major surgery within 4 weeks of planned first dose of the therapeutic investigational product.\n* Prior external beam radiation therapy to more than 25% of the bone marrow.\n* Pregnant, breastfeeding, or unwilling to practice birth control during participation in the study.\n* Any active infection.","ALL","18 Years",{"count":92,"type":93},115,"ESTIMATED","INTERVENTIONAL",[96],"PHASE1","This is a Phase 1-1b multicenter clinical study to evaluate the safety, efficacy, and dosimetry of \\[177Lu\\]Lu-A9-0631 and \\[225Ac\\]Ac-0642 in participants with Gastrin-Releasing Peptide Receptor (GRPR) expressing locally advanced, unresectable or metastatic solid tumors.",[99,100,101,102],"Breast Cancer","Prostate Cancer","Colorectal Cancer","GRPR-positive Solid Tumors",[104,105,106,107,108,109],"breast cancer","prostate cancer","colorectal cancer (CRC)","GRPR-positive solid tumors","radiopharmaceuticals","theranostics","2026-06-16",{"date":112,"type":113},"2026-06-22","ACTUAL",{"date":115,"type":93},"2026-07-01",{"date":117,"type":93},"2029-12",{"name":5,"class":6},2]